Company Encyclopedia
View More
name
CABIO
688089.SH
Cabio Biotech (Wuhan) Co., Ltd. develops, produces, and markets arachidonic and docosahexaenoic acids, and beta-carotene for domestic and foreign infant formula, and healthy food manufacturers. It offers human and animal nutrition, personal care, and synthetic biology products. The company was founded in 1999 and is based in Wuhan, the People’s Republic of China.
1.931 T
688089.SHMarket value -Rank by Market Cap -/-

Financial Score

11/12/2025 Update
B
Specialty ChemicalsIndustry
Industry Ranking43/154
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE10.76%B
    • Profit Margin28.45%A
    • Gross Margin47.35%B
  • Growth ScoreB
    • Revenue YoY17.85%B
    • Net Profit YoY47.73%B
    • Total Assets YoY9.50%B
    • Net Assets YoY6.36%B
  • Cash ScoreB
    • Cash Flow Margin351.55%C
    • OCF YoY17.85%B
  • Operating ScoreD
    • Turnover0.34D
  • Debt ScoreA
    • Gearing Ratio10.06%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    12:11 ET CABIO präsentiert auf der Fi Europe 2025 in Paris Innovationen im Bereich Lebensphasenernährung und eröffnet gleichzeitig seinen neuen globalen Hauptsitz

    CABIO, a leading Chinese biotechnology company, showcased its extensive portfolio of nutritional supplements at the 30th Food Ingredients Europe 2025 in Paris. Concurrently, CABIO announced the opening of its new global headquarters, the Wuhan Synthetic Biology Innovation Hub. This new hub aims to deepen innovation, enhance collaboration, and amplify impact in synthetic biology. CABIO's product lines include CABIO®ARA, CABIO®Omega-3, Keyshine®HMOs 2'-FL, and Keyshine®N-Acetylneuraminic Acid. The new headquarters will support CABIO's global expansion and sustainable development in the nutrition and health industry.

    prnewswire·
    SH
    688089
    -0.52%
    prnewswire·
    SH
    688089
    -0.52%

    CABIO: Cumulatively spent CNY 27.9213 million to repurchase 0.63% of the company's shares

    CABIO announced that the company will initiate the second phase of share repurchase in 2025, intending to repurchase shares for equity incentives with an amount ranging from 15 million to 30 million yuan. As of a certain time in 2025, a total of 1,060,573 shares have been repurchased, accounting for 0.63% of the total share capital, with a cumulative repurchase amount of 27.9213 million yuan, and the repurchase price ranging between 23.52 yuan/share and 28.58 yuan/share, in compliance with relevant regulations and repurchase plan requirements. The company will continue to advance the repurchase as required and disclose progress in a timely manner

    Zhitong·
    SH
    688089
    -0.52%
    Zhitong·
    SH
    688089
    -0.52%

    CABIO: Third quarter net profit of 21.3942 million yuan, a year-on-year increase of 33.70%

    CABIO announced that its revenue for the third quarter was 121 million yuan, a year-on-year decrease of 3.97%; net profit was 21.3942 million yuan, a year-on-year increase of 33.70%. Revenue for the first three quarters was 428 million yuan, a year-on-year increase of 10.56%; net profit was 129 million yuan, a year-on-year increase of 54.18%

    Zhitong·
    SH
    688089
    -0.52%
    Zhitong·
    SH
    688089
    -0.52%

    CABIO expects a profit increase, with a projected year-on-year growth of 53.77% in net profit attributable to the parent company for the first three quarters

    CABIO expects a net profit attributable to the parent company of approximately 129 million yuan in the first three quarters, a year-on-year increase of 53.77%. The growth in performance is mainly attributed to the increase in sales of ARA and algal oil DHA products to domestic customers, as well as improvements in production efficiency and product structure optimization

    Zhitong·
    SH
    688089
    -0.52%
    Zhitong·
    SH
    688089
    -0.52%

    The dairy powder concept has seen unusual fluctuations, with Zhuangyuan Pasture hitting the limit-up

    The dairy powder concept has seen unusual movements, with Zhuangyuan Pasture hitting the limit up, and CABIO, Knight Dairy, PINLIVE, MQR, Yiming Foods, and Beingmate also rising

    Zhitong·
    SZ
    002910
    -4.63%
    SH
    688089
    -0.52%
    SZ
    300892
    -5.16%
    Zhitong·
    SZ
    002910
    -4.63%
    SH
    688089
    -0.52%
    SZ
    300892
    -5.16%
    © 2025 Longbridge｜Disclaimer